What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Disease
- Rheumatoid arthritis
His main research concerns Rheumatoid arthritis, Internal medicine, Arthritis, Surgery and Gastroenterology.
The various areas that Joel M. Kremer examines in his Rheumatoid arthritis study include Methotrexate and Cohort study.
His Internal medicine study typically links adjacent topics like Placebo.
Joel M. Kremer interconnects Adverse effect, Randomized controlled trial, Janus kinase inhibitor and Clinical trial in the investigation of issues within Placebo.
His Arthritis study incorporates themes from Endocrinology and Connective tissue disease.
Joel M. Kremer has researched Rheumatology in several fields, including Psoriatic arthritis and Pharmacokinetics.
His most cited work include:
- A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. (1880 citations)
- Genetics of rheumatoid arthritis contributes to biology and drug discovery (1350 citations)
- 2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease‐modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis (1286 citations)
What are the main themes of his work throughout his whole career to date?
Joel M. Kremer spends much of his time researching Rheumatoid arthritis, Internal medicine, Rheumatology, Methotrexate and Arthritis.
His Rheumatoid arthritis study integrates concerns from other disciplines, such as Physical therapy, Randomized controlled trial and Cohort.
His Internal medicine study combines topics in areas such as Gastroenterology, Placebo and Surgery.
His Placebo research is multidisciplinary, incorporating perspectives in Tolerability, Tofacitinib, Janus kinase inhibitor and Clinical trial.
His studies deal with areas such as Discontinuation, Disease, Prednisone, Severity of illness and Abatacept as well as Rheumatology.
The Methotrexate study combines topics in areas such as Pharmacokinetics, Combination therapy, Pharmacology, Drug and Chemotherapy.
He most often published in these fields:
- Rheumatoid arthritis (79.06%)
- Internal medicine (76.47%)
- Rheumatology (28.24%)
What were the highlights of his more recent work (between 2015-2021)?
- Internal medicine (76.47%)
- Rheumatoid arthritis (79.06%)
- Rheumatology (28.24%)
In recent papers he was focusing on the following fields of study:
His scientific interests lie mostly in Internal medicine, Rheumatoid arthritis, Rheumatology, In patient and Arthritis.
His Internal medicine research includes themes of Placebo and Physical therapy.
His research in Placebo intersects with topics in Clinical endpoint, Clinical trial, Adverse effect and Severity of illness.
The concepts of his Rheumatoid arthritis study are interwoven with issues in Discontinuation, Methotrexate and Disease.
His work in Methotrexate addresses issues such as Gastroenterology, which are connected to fields such as C-reactive protein.
His Rheumatology study combines topics from a wide range of disciplines, such as Odds ratio, Disease activity, Surgery, Quality of life and Confidence interval.
Between 2015 and 2021, his most popular works were:
- Baricitinib in Patients with Refractory Rheumatoid Arthritis (290 citations)
- Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial (189 citations)
- Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial (130 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Disease
- Rheumatoid arthritis
Joel M. Kremer mostly deals with Internal medicine, Rheumatoid arthritis, Rheumatology, Placebo and Arthritis.
His Internal medicine research is multidisciplinary, incorporating elements of Physical therapy and Surgery.
His work carried out in the field of Rheumatoid arthritis brings together such families of science as Gastroenterology, Methotrexate and Clinical trial.
His Rheumatology research is multidisciplinary, relying on both Psoriatic arthritis, Disease, Epidemiology and Cohort.
His Placebo research includes elements of Clinical endpoint, Severity of illness and Endocrinology, Cholesterol.
Disease-modifying antirheumatic drug, Diabetes mellitus and Proportional hazards model is closely connected to Hazard ratio in his research, which is encompassed under the umbrella topic of Arthritis.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
